Background: The viral broad spectrum chemokine vCCL2/vMIP-II binds to CXCR4 and CXCR7 and protects host cells against HIV-1 infection. Peptide derived from vCCL2 N-terminus (vCCL21-21) displays modest CXCR4 binding affinity and antiviral properties compared to the parental chemokine but mutations within its CC motif have been shown to enhance its antiviral properties. In this study, we selected new vCCL2 derived peptides by means of phage display and further optimized them by rational designMethods: A vCCL21-21 phage library in which cysteine at positions 11 and 12 (C11C12) (Mimokine) were fully randomized was first engineered and screened against CXCR4-proteoliposomes. The most potent selected Mimokines were then further optimized by D-amino acid replacement and dimerization. Finally, a set of L- and D-bivalent ligands were evaluated for their CXCR4/CXCR7 binding and antiviral propertiesResults: Selection of vCCL21-21 library on CXCR4 resulted in the isolation of 4 Mimokines bearing FR, SR, VR and WL residues at positions C11 and C12. These Mimokines fully protected MT-4 cells against infection by a HIV-1 X4 virus (HXB2) (IC50= 60 to 185 µM) and exhibited 3 to 4-fold higher affinity for CXCR4 (IC50= 480 to 740 nM) than the reference Mimokine SS (IC50= 2164 nM). Molecular modelling and docking into CXCR4 3D structure suggested that the enhanced affinity of Mimokines FR, SR and VR for CXCR4 might be due to the formation of an additional salt bridge between the Mimokine Arg12 and the receptor sulfated Tyr21. The potency of the selected Mimokines was further enhanced by combining dimerization and D-amino acid substitution. Bivalent Mimokines SR, VR, FR and WL in D format exhibited 10 to 20-fold increase in CXCR4 binding affinity (IC50= 29 to 44 nM) and 20 to 100-fold increase in antiviral activities (IC50 = 1,8 to 6.3 µM) when compared to their respective monomeric L-counterparts. Interestingly, these bivalent D-Mimokines displayed a 100-fold reduction in binding CXCR7 (IC50 = 5630 nM) when compared to the bivalent L-Mimokines, demonstrating that D-amino acid replacement improved both affinity and selectivity for CXCR4Conclusions: Optimized bivalent D-Mimokines displayed 10 to 20-fold enhanced CXCR4 affinity and 20 to 100-fold improved antiviral properties when compared to the initial monomeric L-Mimokines. These bivalent D-Mimokines showed a reduced affinity for CXCR7 and may therefore serve as lead compounds for the further development of more selective CXCR4 HIV-1 inhibitors